The novel mechanism of lenalidomide activity
Lenalidomide acts by a novel drug mechanism—modulation of the substrate specificity of the CRL4[CRBN] E3 ubiquitin ligase. In multiple myeloma, lenalidomide induces the ubiquitination of IKZF1 and IKZF3 by CRL4[CRBN] . Subsequent proteasomal ...
Blood . 2015 Oct 5;126(21):2366–2369. doi: 10.1182/blood-2015-07-567958 The novel mechanism of lenalidomide activity Emma C Fink Emma C Fink 1 Brigham and Women’s Hospital, Division of Hematology, Boston, MA Find articles by Emma C Fink 1 , Benjamin L Ebert Benjamin L Ebert 1 Brigham and Women’s Hospital, Division of Hematology, Boston, MA Find articles by Benjamin L Ebert 1, ✉ Author information Article notes Copyright and License information 1 Brigham and Women’s Hospital, Division of Hematology, Boston, MA ✉ Corresponding author. Received 2015 Jul 1; Accepted 2015 Sep 23; Issue date 2015 No
saved by
related reading
- Targeting telomerase for cancer therapy | Oncogenenature.com
- Lysosome-targeting chimeras evolve | Nature Chemical Biologynature.com
- Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemianature.com
- Imidazole ketone erastin induces ferroptosis and slows tumor growth in a mouse lymphoma modelpmc.ncbi.nlm.nih.gov
- The blood cancer that became solvableworksinprogress.news
- PDB101: Molecule of the Month: PROTACs and Molecular Glue Degraderspdb101.rcsb.org
- Summing up cancer stem cellsnature.com
- Guidance for Industryfda.gov
- Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangementsnature.com
- Molecular Medicine Reportsspandidos-publications.com
- RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia - PubMedpubmed.ncbi.nlm.nih.gov
- Sensitizing to Venetoclax treatmentmappingignorance.org